Patents by Inventor Lauri Kangas
Lauri Kangas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11638722Abstract: The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.Type: GrantFiled: January 14, 2022Date of Patent: May 2, 2023Assignee: THERAPEUTICA BOREALIS OY C/O AVANCE ATTORNEYS LTD.Inventors: Kalervo Väänänen, Lauri Kangas, Matti Rihko
-
Publication number: 20220133784Abstract: The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.Type: ApplicationFiled: January 14, 2022Publication date: May 5, 2022Inventors: Kalervo VÄÄNÄNEN, Lauri KANGAS, Matti RIHKO
-
Patent number: 11278602Abstract: The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.Type: GrantFiled: March 22, 2021Date of Patent: March 22, 2022Assignee: THERAPEUTICA BOREALIS OYInventors: Kalervo Väänänen, Lauri Kangas, Matti Rihko
-
Publication number: 20210299230Abstract: The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.Type: ApplicationFiled: March 22, 2021Publication date: September 30, 2021Inventors: Kalervo VÄÄNÄNEN, Lauri KANGAS, Matti RIHKO
-
Patent number: 11007187Abstract: The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.Type: GrantFiled: May 11, 2020Date of Patent: May 18, 2021Assignee: THERAPEUTICA BOREALIS OYInventors: Kalervo Väänänen, Lauri Kangas, Matti Rihko
-
Patent number: 10377791Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 25, 2014Date of Patent: August 13, 2019Assignee: FORENDO PHARMA LTD.Inventors: Maire Eloranta, Leena Hirvelä, Lauri Kangas, Pasi Koskimies, Risto Lammintausta, Mikko Unkila
-
Patent number: 9850272Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 25, 2014Date of Patent: December 26, 2017Assignee: FORENDO PHARMA LTD.Inventors: Leena Hirvelä, Lauri Kangas, Pasi Koskimies, Risto Lammintausta, Mikko Unkila
-
Patent number: 9663549Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 25, 2014Date of Patent: May 30, 2017Assignee: FORENDO PHARMA LTD.Inventors: Maire Eloranta, Leena Hirvelä, Lauri Kangas, Pasi Koskimies, Risto Lammintausta, Mikko Unkila
-
Publication number: 20170114090Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 25, 2014Publication date: April 27, 2017Applicant: FORENDO PHARMA LTDInventors: Maire ELORANTA, Leena HIRVELÄ, Lauri KANGAS, Pasi KOSKIMIES, Risto Lammintausta, Mikko Unkila
-
Publication number: 20170081357Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 25, 2014Publication date: March 23, 2017Applicant: FORENDO PHARMA LTDInventors: Maire ELORANTA, Leena HIRVELÄ, Lauri KANGAS, Pasi KOSKIMIES, Risto LAMMINTAUSTA, Mikko UNKILA
-
Publication number: 20170081356Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 25, 2014Publication date: March 23, 2017Applicant: FORENDO PHARMA LTDInventors: Leena HIRVELÄ, Lauri KANGAS, Pasi KOSKIMIES, Risto LAMMINTAUSTA, Mikko UNKILA
-
Patent number: 9566252Abstract: This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.Type: GrantFiled: July 15, 2010Date of Patent: February 14, 2017Assignee: HORMOS MEDICAL LTD.Inventors: Kaija Halonen, Lauri Kangas, Michael W. DeGregorio
-
Publication number: 20140142195Abstract: This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.Type: ApplicationFiled: January 24, 2014Publication date: May 22, 2014Applicants: HORMOS MEDICAL LTD.Inventors: Kaija HALONEN, Lauri KANGAS, Michael W. DEGREGORIO
-
Patent number: 7528166Abstract: Novel phenolic esters of lignans, and pharmaceutical compositions, dietary supplements, and food products containing these esters.Type: GrantFiled: January 21, 2003Date of Patent: May 5, 2009Assignee: Hormos Medical CorporationInventors: Patrik Eklund, Mervi Hiilovaara-Teijo, Arja Kalapudas, Lauri Kangas, Anna Lindholm, Rainer Sjohölm, Marja Södervall, Mikko Unkila
-
Patent number: 7008666Abstract: The invention relates to a method of inhibiting myeloperoxidase activity in neutrophils in an individual by administering to the individual an effective amount of a lignan, where said lignan is enterolactone. The invention is further directed to a method inhibiting myeloperoxidase activity or oxidative burst of macrophages in an individual by administering to the individual an effective amount of a lignan where said lignan is enterolactone or hydroxymatairesinol or a mixture. Finally, the invention is directed to a method of inhibiting oxidative burst or myeloperoxidase activity in neutrophils in an individual by administering to the individual an effective amount of a lignan which is hydroxymatairesinol.Type: GrantFiled: November 26, 2001Date of Patent: March 7, 2006Assignee: Hormos Nutraceutical Oy Ltd.Inventors: Markku Ahotupa, John Eriksson, Lauri Kangas, Mikko Unkila, Janne Komi, Merja Perälä, Helena Korte
-
Patent number: 7005447Abstract: A food product containing an effective amount of an active agent which is hydroxymatairesinol, a geometric isomer or stereoisomer thereof, or an acceptable salt thereof, or a mixture thereof, where the food product is selected from the group consisting of a nutritional supplement and a nutrient. The food product can increase the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on the administration of hydroxymatairesinol to the person.Type: GrantFiled: August 13, 2003Date of Patent: February 28, 2006Assignee: Hormos Nutraceutical Oy Ltd.Inventors: Markku Ahotupa, Christer Eckerman, Lauri Kangas, Sari Mäkelä, Niina Saarinen, Risto Santti, Anni Wärri
-
Publication number: 20050187302Abstract: This invention relates to a method for the treatment or prevention of osteoporosis in an individual suffering from increased bone turnover, said method comprising administering to said individual an effective amount of a therapeutically active compound, which is a selective estrogen receptor modulator of the triphenylalkene or triphenylalkane structure.Type: ApplicationFiled: February 23, 2004Publication date: August 25, 2005Applicant: Hormos Medical CorporationInventors: Taru Blom, Lauri Kangas, Risto Lammintausta
-
Publication number: 20050101541Abstract: Novel phenolic esters of lignans, and pharmaceutical compositions, dietary supplements, and food products containing these esters.Type: ApplicationFiled: January 21, 2003Publication date: May 12, 2005Inventors: Patrik Eklund, Mervi Hiilovaara-Teijo, Arja Kalapudas, Lauri Kangas, Anna Lindholm, Rainer Sjoholm, Marja Sodervall, Mikko Unkila
-
Patent number: 6875775Abstract: The invention provides novel selective estrogen receptor modulator compounds of the general formula: wherein R1 and R2, which are the same or different are a) H, halogen, OCH3, OH; or where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, —CH2C?CH or —CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or c) —Y—(CH2)nCH2—O—R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, —CH2CH2OH, or —CH2CH2Cl; or d) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and ?R3 is H, halogen, OH or —OCH3; stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.Type: GrantFiled: April 8, 2003Date of Patent: April 5, 2005Assignee: Hormos Medical Oy LTDInventors: Marja-Liisa Södervall, Arja Kalapudas, Lauri Kangas, Risto Lammintausta, Pirkko Härkönen, Kalervo Väänänen, Arto Karjalainen
-
Patent number: 6723738Abstract: The invention provides novel selective estrogen receptor modulator compounds of the general formula: wherein R1 and R2 , which are the same or different are a) H, halogen, OCH3, OH; or where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, —CH2C≡CH or —CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or c) —Y—(CH2)nCH2—O—R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, —CH2CH2OH, or —CH2CH2Cl; or d) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or —OCH3; stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.Type: GrantFiled: April 8, 2003Date of Patent: April 20, 2004Assignee: Hormos Medical Oy LtdInventors: Marja-Liisa Södervall, Arja Kalapudas, Lauri Kangas, Risto Lammintausta, Pirkko Härkönen, Kalervo Väänänen